Evidence map›Paper›PMID 34867944›Full record

Observational studyFrontiers in immunology2021

Methotrexate Treatment of Newly Diagnosed RA Patients Is Associated With DNA Methylation Differences at Genes Relevant for Disease Pathogenesis and Pharmacological Action.

Kari Guderud, Line H Sunde, Siri T Flåm, Marthe T Mæhlen, Maria D Mjaavatten, Ellen S Norli, Ida M Evenrød, Bettina K Andreassen, Sören Franzenburg, Andre Franke and 3 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Methylation of T and B Lymphocytes in Autoimmune Rheumatic Diseases.Clinical reviews in allergy & immunology · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Kari GuderudDepartment of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway.
Line H SundeDepartment of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway.
Siri T FlåmDepartment of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway.
Marthe T MæhlenDepartment of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
Maria D MjaavattenDepartment of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
Ellen S NorliDepartment of Rheumatology, Martina Hansens Hospital, Bærum, Norway.
Ida M EvenrødDepartment of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway.
Bettina K AndreassenDepartment of Research, Cancer Registry of Norway, Institute for Population-Based Research, Oslo, Norway.
Sören FranzenburgInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Andre FrankeInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Simon RaynerDepartment of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway.
Kristina GervinPharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway.
Benedicte A LieDepartment of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway.
Oslo University Hospital · NOUniversity of Oslo · NOChristian-Albrechts-Universität zu Kiel · DEDiakonhjemmet Hospital · NOCancer Registry of Norway · NOMartina Hansens Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methotrexate (MTX) is the first line treatment of rheumatoid arthritis (RA), and methylation changes in bulk T cells have been reported after treatment with MTX. We have investigated cell-type specific DNA methylation changes across the genome in naïve and memory CD4 Results: We found that MTX treatment significantly influenced DNA methylation levels at multiple CpG sites in both cell populations. Interestingly, we identified differentially methylated sites annotated to two genes; Conclusion: We detected CpG sites that were associated with MTX treatment in CD4

Indexed as

AdultAgedAntirheumatic AgentsArthritis, RheumatoidCD4-Positive T-LymphocytesCpG IslandsDNA-Binding ProteinsDNA MethylationFemaleHumansIntracellular Signaling Peptides and ProteinsMaleMemory T CellsMethotrexateMiddle AgedReceptors, CCR6Antirheumatic AgentsCCR6 protein, humanDNA-Binding ProteinsIntracellular Signaling Peptides and ProteinsMethotrexateReceptors, CCR6Receptors, Cell SurfaceSORCS2 protein, humanSTAT3 protein, humanSTAT3 Transcription FactorSynaptogyrinsSYNGR1 protein, humantripartite motif-containing protein 15, humanWDFY4 protein, humanCD4 memoryCD4 naïveDNA methylationepigeneticsmethotrexateRheumatoid arthritisRRBST cells

Identifiers

PMID34867944
PMCPMC8637827
OpenAlexW3214406674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.